Anales de la RANM

239 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 ACTUALIZACIÓN DE ANTICOAGULACIÓN EN FIBRILACIÓN ARTICULAR Antoñana Ugalde S, et al. An RANM. 2024;141(03): 232 - 2 42 pero debemos individualizar la idoneidad de iniciar anticoagulación en este contexto a falta de evidencia sólida. BIBLIOGRAFÍA 1. Benjamin EJ, Muntner P, Alonso A et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10): e56-528. 2. Van Gelder IC, Rienstra M, Bunting K V et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio- Thoracic Surgery (EACTS). Eur Heart J [In- ternet]. 2024; 45(36): 3314-3414. Available from: https://academic.oup.com/eurheartj/ar- ticle/45/36/3314/7738779 3. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: Systematic review and meta-analy- sis. BMJ. 2016; 354: i4482. 4. Van der Endt VHW, Milders J, Penning de Vries BBL et al. Comprehensive comparison of stroke risk score performance: a systematic review and meta-analysis among 6 267 728 pa- tients with atrial fibrillation. Europace. 2022; 24(11): 1739-1753. 5. Joglar JA, Chung MK, Armbruster AL et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial Fi- brillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guide- lines. Circulation. 2024;149(1): e1-e156. doi: 10.1161/CIR.0000000000001193. 6. Bassand JP, Accetta G, Al Mahmeed W et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Ra- tionale for comprehensive management of atrial fibrillation. PLoS One. 2018; 13(1): e0191592. 7. Paciaroni M, Agnelli G, Falocci N et al. Prog- nostic value of trans-thoracic echocardiogra- phy in patients with acute stroke and atrial fibrillation: Findings from the RAF study. J Neurol. 2016; 263(2): 231-237. 8. Seiffge DJ, De Marchis GM, Koga M et al. Is- chemic stroke despite oral anticoagulant thera- py in patients with atrial fibrillation. Ann Neu- rol. 2020; 87(5): 677-687. 9. Ocak G, Khairoun M, Khairoun O et al. Chro- nic kidney disease and atrial fibrillation: a dan- gerous combination. PLoS One. 2022; 17(4): e0266046. 10. Tomasdottir M, Friberg L, Hijazi Z, Lindbäck J, Oldgren J. Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019; 42(10): 1003-1009. 11. Wu VCC, Wu M, Aboyans V et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart. 2020; 106(7): 534-540. 12. Mikkelsen AP, Lindhardsen J, Lip GYH, Gisla- son GH, Torp-Pedersen C, Olesen JB. Female sex as a risk factor for stroke in atrial fibrilla- tion: a nationwide cohort study. J Thromb Hae- most. 2012;10(9):1745-1751. 13. Hindricks G, Potpara T, Kirchhof P et al. 2020 ESC Guidelines for the diagnosis and manage- ment of atrial fibrillation developed in colla- boration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373-498. 14. Connolly SJ, Ezekowitz MD, Yusuf S et al. da- bigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009; 361(12): 1139-1151. 15. Patel MR, Mahaffey KW, Garg J et al. Rivaro- xaban versus Warfarin in Nonvalvular Atrial Fibrillation. New Engl J Med [Internet]. 2011; 365(10): 883-891. Available from: http://www. nejm.org/doi/10.1056/NEJMoa1009638 16. Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011; 365(11): 981-992. 17. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2013; 369(22): 2093-2104. 18. Nolte CH. Factor XI inhibitors – Rising stars in anti-thrombotic therapy? J Neurol Sci. 2024; 464 :123157. 19. Lipworth K. The AZALEA-TIMI 71 Study and the future of Factor XI Inhibition: Reflections from the American Heart Association Scientific Congress 2023. EMJ Cardiol. 2024; 12(1): 2-8. 20. h t t p s : / / c l i n i c a l t r i a l s . g o v / s t u d y / NCT0 5 7 1 2 2 0 0 ? t e rm=L I LAC%2 0T IMI%2 0 76&rank=1 [Internet]. 2024. Study to EvaLuate the EffIcacy and Safety of AbeLacimab in High- risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral AntiCoagu- lation (LILAC-TIMI 76) (LILAC-TIMI 76). 21. Piccini JP, Caso V, Connolly SJ et al. Safety of the oral factor XIa inhibitor asundexian com- pared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. The Lancet. 2022; 399(10333): 1383-1390. 22. News Release [Internet]. Available from: www. bayer.com. 23. Garrett AD. Dabigatran vs. Warfarin in patients with mechanical heart valves. Drug Topics. 2013. 24. Wang TY, Svensson LG, Wen J et al. Apixaban or Warfarin in Patients with an On-X Mechani- cal Aortic Valve. NEJM Evid. 2023; 2(7): EVI- Doa2300067. 25. Guimarães HP, Lopes RD, de Barros e Silva PGM et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral Valve. New Engl J Med. 2020; 383(22): 2117-2126. 26. Collet JP, Van Belle E, Thiele H et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022; 43(29): 2783-2797. 27. Connolly SJ, Karthikeyan G, Ntsekhe M et al. Rivaroxaban in rheumatic heart disease–as-